SAN DIEGO, July 16, 2019 /PRNewswire/ — Ambrx Inc. today announced that Bristol-Myers Squibb Company (“BMS”) has initiated a phase I clinical trial to evaluate the safety, pharmacokinetics and pharmacodynamics of long-acting Relaxin for the potential treatment of heart failure (“HF”). Long-acting Relaxin is […]